Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau — Clinical Trial Site

11 Registered trials

6 Currently recruiting

Organisation

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Location

Barcelona, Spain

Identifier

ORG-100043040

Address

Calle Sant Quinti 77-79, 08041, Spain

Departments

CIM
CIM Sant Pau
Clinical Pharmacology
Institut de Recerca - CIM-Sant Pau
Neurology
Oncología Médica
Radiotherapy oncology service
Servicio de Hematología
Servicio de Neurologia

Clinical trials at this site (11)

Search interface

A phase I Study to Assess the Safety and Tolerability of MBF-362 in Healthy Women, and Preliminary Efficacy in Otherwise Healthy Women diagn… Recruiting

2025-521809-40-00 Primary Dysmenorrhea 3 2025-12-10
A Phase I double blinded, single-center, randomized, crossover study comparing the PK, PD, safety and tolerability of a single IV dose (1µg/… Recruiting

2024-518285-27-00 Not applicable (submitted trial is a bioequivalence stu 2 2025-12-01
Early treatment of irregular heartbeat (atrial fibrillation) to prevent a recurrent stroke Recruiting

2025-521260-35-00 acute ischemic stroke and atrial fibrillation (AF) 6 2025-11-07
A Phase I, randomized, consecutive dose, double blind, parallel study comparing the PK, PD, immunogenicity, safety and tolerability of LB-07… Recruiting

2024-518286-95-00 Not applicable (submitted trial is a bioequivalence stu 2 2025-07-02
Use of statins in patients with intracerebral hemorrhage Recruiting

2024-511465-11-00 Spontaneous lobar ICH 5 2024-11-20
A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi… Recruiting

2023-509851-15-00 Colon cancer 5 2024-10-22
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin… Ended

2023-503467-41-00 Relapsed or Refractory Multiple Myeloma 5 2022-10-12
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended

2023-505246-26-00 High- or very-high risk, localized or locally advanced 5 2016-01-27
A clinical trial to compare three oral treatments and a placebo in preventing skin reactions caused by histamine in healthy volunteers Ended

2024-516569-35-00 Allergy 6 2025-05-09
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Ep… Ended

2022-503067-15-00 Tuberous Sclerosis Complex (TSC) related epilepsy 5 2023-10-02
A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years old Ended

2024-513885-20-00 Insomnia Disorder 4 2022-12-05